|
Bivariate analysis of risk factors for in-hospital mortality |
||||
| Factor |
Nonsurvivors (n = 52) |
Survivors (n = 172) |
RR (95% CI) |
P |
|
|
||||
| Sex |
0.46 (0.28–0.74) |
0.007 |
||
| Male |
21 (40.4) |
106 (61.6) |
||
| Female |
31 (59.6) |
66 (38.4) |
||
| Age (years)a |
61.5 (47.2–71.7) |
67 (56.5–75.7) |
0.09 |
|
| Hepatic cirrhosis |
5 (9.6) |
9 (5.2) |
1.93 (0.48–6.75) |
0.32 |
| Immunosuppression |
5 (9.6) |
4 (2.3) |
4.47 (0.91–23.25) |
0.03 |
| COPD |
5 (9.6) |
17 (9.9) |
0.97 (0.27–2.93) |
0.95 |
| End-stage renal disease |
5 (9.6) |
7 (4.1) |
2.51 (0.6–9.62) |
0.15 |
| Chronic cardiac failure |
2 (3.8) |
3 (1.7) |
2.25 (0.18–20.16) |
0.33 |
| Diabetes mellitus |
13 (25) |
44 (25.6) |
0.97 (0.45–2.09) |
0.93 |
| Noncured malignancy |
8 (15.4) |
4 (2.3) |
1.92 (7.64–35.84) |
0.001 |
| Alcoholism |
5(9.6) |
18 (10.5) |
0.91 (0.25–2.73) |
0.86 |
| Smoking habit |
8 (15.4) |
41 (23.8) |
0.65 (0.33–1.29) |
0.25 |
| APACHE IIa |
18.5 (14–23.75) |
12 (8–17) |
<0.001 |
|
| APACHE II admission ICUa,b |
22.5 (18–26) |
15.5 (10–19.75) |
<0.001 |
|
| SOFA (1)a,c |
6 (3–11) |
3 (1–7) |
<0.001 |
|
| SOFA admission ICUa,b |
10.5 (6.75–14) |
6 (3–9.25) |
<0.001 |
|
| Bacteraemia |
13 (25) |
43 (25) |
1 (0.46–2.16) |
1 |
| Site of infection |
||||
| Urologic |
4 (7.7) |
30 (17.5) |
0.39 (0.1–1.21) |
|
| Central nervous system |
3 (5.7) |
10 (5.8) |
0.75 (0.13–2.84) |
|
| Other |
0 (0) |
4 (2.3) |
0 (0–5.04) |
|
| Soft tissue |
3 (5.8) |
14 (8.1) |
0.69 (0.12–2.63) |
|
| Abdomen |
23 (44.2) |
59 (34.3) |
1.52 (0.77–2.99) |
|
| Unknown |
4 (7.7) |
5 (2.9) |
2.78 (0.53–13.42) |
|
| Lung |
15 (28.8) |
50 (29.1) |
0.67 (0.32–1.37) |
|
| Genotype |
||||
| -308 TNF-α promoter polymorphism |
1.28 (0.49–3.46) |
0.59 |
||
| GG |
45 (86.5) |
141 (82%) |
||
| GA/AA |
7 (13.5) |
31 (18) |
||
| TNF-β (NcoI polymorphism) |
0.74 (0.37–1.5) |
0.37 |
||
| GG/GA |
17 (33.7) |
68 (39.6) |
||
| AA |
35 (67.3) |
104 (60.4) |
||
| IL-10-1082 |
0.7 (0.22–1.88) |
0.42 |
||
| GG |
6 (11.6) |
27 (15.7) |
||
| GA/AA |
46 (88.4) |
145 (84.3) |
||
| Genotype -308 TNF GA/AA, TNF-β AA, IL-10-1082 GG |
0.92 (0.45–1.84) |
0.8 |
||
| Yes |
18 (34.1) |
63 (36.6) |
||
| No |
34 (65.4) |
109 (63.4) |
||
| Empirical antibiotic therapy |
<0.001 |
|||
| Adequate |
24 (46.1) |
118 (68.6) |
0.39 (0.20–0.77) |
|
| Inadequate |
12 (23.1) |
4 (2.3) |
12.6 (3.53–55.57) |
|
| Not evaluable |
16 (30.8) |
50 (29.1) |
1.08 (0.52–2.24) |
|
| Delayed surgical interventiona,d |
16 (7–36) |
12.5 (8–24) |
0.77 |
|
| Delayed of AATa |
7 (4–28) |
5 (3–10) |
0.008 |
|
|
Unless otherwise stated, values are expressed as n (%). aResults expressed as median (25th to 75th percentiles). bOnly 178 patients were admitted to the ICU. c SOFA (1) means SOFA score in the first 24 hours in the hospital. dOnly in 'surgical patients' (n = 93). AAT, appropriate antibiotic therapy; APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; RR, relative risk; SOFA, Sequential Organ Failure Assessment. | ||||
Garnacho-Montero et al. Critical Care 2006 10:R111 doi:10.1186/cc4995 |
||||